CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

AngioDynamics, Inc.

ANGO
$646MSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for ANGO. That does not mean none is planned.

Get an email about ANGO's next catalysts

Track AngioDynamics (ANGO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

1 upcoming event in our data (earnings).See the timeline

Catalyst Timeline

1 upcoming, 0 past

Earnings

ANGO Earnings Report

January 2027~

Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.11 | FQ end Nov/2026 | Call: tbd

Market Overview

Stock performance and key metrics

NASDAQSurgical & Medical Instruments & ApparatusπŸ‡ΊπŸ‡ΈNorth AmericaLATHAM675 employees
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in AngioDynamics, Inc.'s drug pipeline?β†’

CatalystAlert tracks 2 drug candidates in AngioDynamics, Inc.'s (ANGO) pipeline across Phase 3, Phase 2. Its lead program is Modified FOLFIRINOX Regimen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is AngioDynamics, Inc.'s next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for AngioDynamics, Inc. (ANGO) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track ANGO biotech catalysts?β†’

Add ANGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AngioDynamics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply